# Optimizing Metformin Use in Polycystic Ovary Syndrome

> **NCT07120815** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Helsinki University Central Hospital** · enrollment: 184 (estimated)

## Conditions studied

- Polycystic Ovary Syndrome (PCOS)

## Interventions

- **DRUG:** Metformin 1500 mg daily
- **DRUG:** Metformin 2250 mg daily

## Key facts

- **NCT ID:** NCT07120815
- **Lead sponsor:** Helsinki University Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2025-08-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07120815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07120815, "Optimizing Metformin Use in Polycystic Ovary Syndrome". Retrieved via AI Analytics 2026-06-27 from https://api.ai-analytics.org/clinical/NCT07120815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*